### SUBPART 10—FEES RELATING TO OVER-THE-COUNTER DRUGS

### §379j–71. Definitions
* In this subpart:

  * (1) The term "affiliate" means a business entity that has a relationship with a second business entity if, directly or indirectly—

    * (A) one business entity controls, or has the power to control, the other business entity; or

    * (B) a third party controls, or has power to control, both of the business entities.


  * (2) The term "contract manufacturing organization facility" means an OTC monograph drug facility where neither the owner of such manufacturing facility nor any affiliate of such owner or facility sells the OTC monograph drug produced at such facility directly to wholesalers, retailers, or consumers in the United States.

  * (3) The term "costs of resources allocated for OTC monograph drug activities" means the expenses in connection with OTC monograph drug activities for—

    * (A) officers and employees of the Food and Drug Administration, contractors of the Food and Drug Administration, advisory committees, and costs related to such officers, employees, and committees and costs related to contracts with such contractors;

    * (B) management of information, and the acquisition, maintenance, and repair of computer resources;

    * (C) leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, scientific equipment, and other necessary materials and supplies; and

    * (D) collecting fees under section 379j–72 of this title and accounting for resources allocated for OTC monograph drug activities.


  * (4) The term "FDA establishment identifier" is the unique number automatically generated by Food and Drug Administration's Field Accomplishments and Compliance Tracking System (FACTS) (or any successor system).

  * (5) The term "OTC monograph drug" means a nonprescription drug without an approved new drug application which is governed by the provisions of section 355h of this title.

  * (6) The term "OTC monograph drug activities" means activities of the Secretary associated with OTC monograph drugs and inspection of facilities associated with such products, including the following activities:

    * (A) The activities necessary for review and evaluation of OTC monographs and OTC monograph order requests, including—

      * (i) orders proposing or finalizing applicable conditions of use for OTC monograph drugs;

      * (ii) orders affecting status regarding general recognition of safety and effectiveness of an OTC monograph ingredient or combination of ingredients under specified conditions of use;

      * (iii) all OTC monograph drug development and review activities, including intra-agency collaboration;

      * (iv) regulation and policy development activities related to OTC monograph drugs;

      * (v) development of product standards for products subject to review and evaluation;

      * (vi) meetings referred to in section 355h(i) of this title;

      * (vii) review of labeling prior to issuance of orders related to OTC monograph drugs or conditions of use; and

      * (viii) regulatory science activities related to OTC monograph drugs.


    * (B) Inspections related to OTC monograph drugs.

    * (C) Monitoring of clinical and other research conducted in connection with OTC monograph drugs.

    * (D) Safety activities with respect to OTC monograph drugs, including—

      * (i) collecting, developing, and reviewing safety information on OTC monograph drugs, including adverse event reports;

      * (ii) developing and using improved adverse event data-collection systems, including information technology systems; and

      * (iii) developing and using improved analytical tools to assess potential safety risks, including access to external databases.


    * (E) Other activities necessary for implementation of section 355h of this title.


  * (7) The term "OTC monograph order request" means a request for an order submitted under section 355h(b)(5) of this title.

  * (8) The term "Tier 1 OTC monograph order request" means any OTC monograph order request not determined to be a Tier 2 OTC monograph order request.

  * (9)(A) The term "Tier 2 OTC monograph order request" means, subject to subparagraph (B), an OTC monograph order request for—

    * (i) the reordering of existing information in the drug facts label of an OTC monograph drug;

    * (ii) the addition of information to the other information section of the drug facts label of an OTC monograph drug, as limited by section 201.66(c)(7) of title 21, Code of Federal Regulations (or any successor regulations);

    * (iii) modification to the directions for use section of the drug facts label of an OTC monograph drug, if such changes conform to changes made pursuant to section 355h(c)(3)(A) of this title;

    * (iv) the standardization of the concentration or dose of a specific finalized ingredient within a particular finalized monograph;

    * (v) a change to ingredient nomenclature to align with nomenclature of a standards-setting organization; or

    * (vi) addition of an interchangeable term in accordance with section 330.1 of title 21, Code of Federal Regulations (or any successor regulations).


  * (B) The Secretary may, based on program implementation experience or other factors found appropriate by the Secretary, characterize any OTC monograph order request as a Tier 2 OTC monograph order request (including recharacterizing a request from Tier 1 to Tier 2) and publish such determination in a proposed order issued pursuant to section 355h of this title.

  * (10)(A) The term "OTC monograph drug facility" means a foreign or domestic business or other entity that—

    * (i) is—

      * (I) under one management, either direct or indirect; and

      * (II) at one geographic location or address engaged in manufacturing or processing the finished dosage form of an OTC monograph drug;


    * (ii) includes a finished dosage form manufacturer facility in a contractual relationship with the sponsor of one or more OTC monograph drugs to manufacture or process such drugs; and

    * (iii) does not include a business or other entity whose only manufacturing or processing activities are one or more of the following: production of clinical research supplies, testing, or placement of outer packaging on packages containing multiple products, for such purposes as creating multipacks, when each monograph drug product contained within the overpackaging is already in a final packaged form prior to placement in the outer overpackaging.


  * (B) For purposes of subparagraph (A)(i)(II), separate buildings or locations within close proximity are considered to be at one geographic location or address if the activities conducted in such buildings or locations are—

    * (i) closely related to the same business enterprise;

    * (ii) under the supervision of the same local management; and

    * (iii) under a single FDA establishment identifier and capable of being inspected by the Food and Drug Administration during a single inspection.


  * (C) If a business or other entity would meet criteria specified in subparagraph (A), but for being under multiple management, the business or other entity is deemed to constitute multiple facilities, one per management entity, for purposes of this paragraph.

  * (11) The term "OTC monograph drug meeting" means any meeting regarding the content of a proposed OTC monograph order request.

  * (12) The term "person" includes an affiliate of a person.

  * (13) The terms "requestor" and "sponsor" have the meanings given such terms in section 355h of this title.

### §379j–72. Authority to assess and use OTC monograph fees
#### (a) Types of fees
* Beginning with fiscal year 2021, the Secretary shall assess and collect fees in accordance with this section as follows:

* #### (1) Facility fee
  * #### (A) In general
    * Each person that owns a facility identified as an OTC monograph drug facility on December 31 of the fiscal year or at any time during the preceding 12-month period shall be assessed an annual fee for each such facility as determined under subsection (c).

  * #### (B) Exceptions
    * #### (i) Facilities that cease activities
      * A fee shall not be assessed under subparagraph (A) if the identified OTC monograph drug facility—

        * (I) has ceased all activities related to OTC monograph drugs prior to December 31 of the year immediately preceding the applicable fiscal year; and

        * (II) has updated its registration to reflect such change under the requirements for drug establishment registration set forth in section 360 of this title.

    * #### (ii) Contract manufacturing organizations
      * The amount of the fee for a contract manufacturing organization facility shall be equal to two-thirds of the amount of the fee for an OTC monograph drug facility that is not a contract manufacturing organization facility.

  * #### (C) Amount
    * The amount of fees established under subparagraph (A) shall be established under subsection (c).

  * #### (D) Due date
    * #### (i) For first program year
      * For fiscal year 2021, the facility fees required under subparagraph (A) shall be due on the later of—

        * (I) the first business day of July of 2020; or

        * (II) 45 calendar days after publication of the Federal Register notice provided for under subsection (c)(4)(A).

    * #### (ii) Subsequent fiscal years
      * For each fiscal year after fiscal year 2021, the facility fees required under subparagraph (A) shall be due on the later of—

        * (I) the first business day of June of such year; or

        * (II) the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year.

* #### (2) OTC monograph order request fee
  * #### (A) In general
    * Each person that submits an OTC monograph order request shall be subject to a fee for an OTC monograph order request. The amount of such fee shall be—

      * (i) for a Tier 1 OTC monograph order request, $500,000, adjusted for inflation for the fiscal year (as determined under subsection (c)(1)(B)); and

      * (ii) for a Tier 2 OTC monograph order request, $100,000, adjusted for inflation for the fiscal year (as determined under subsection (c)(1)(B)).

  * #### (B) Due date
    * The OTC monograph order request fees required under subparagraph (A) shall be due on the date of submission of the OTC monograph order request.

  * #### (C) Exception for certain safety changes
    * A person who is named as the requestor in an OTC monograph order shall not be subject to a fee under subparagraph (A) if the Secretary finds that the OTC monograph order request seeks to change the drug facts labeling of an OTC monograph drug in a way that would add to or strengthen—

      * (i) a contraindication, warning, or precaution;

      * (ii) a statement about risk associated with misuse or abuse; or

      * (iii) an instruction about dosage and administration that is intended to increase the safe use of the OTC monograph drug.

  * #### (D) Refund of fee if order request is recategorized as a Tier 2 OTC monograph order request
    * If the Secretary determines that an OTC monograph request initially characterized as Tier 1 shall be re-characterized as a Tier 2 OTC monograph order request, and the requestor has paid a Tier 1 fee in accordance with subparagraph (A)(i), the Secretary shall refund the requestor the difference between the Tier 1 and Tier 2 fees determined under subparagraphs (A)(i) and (A)(ii), respectively.

  * #### (E) Refund of fee if order request refused for filing or withdrawn before filing
    * The Secretary shall refund 75 percent of the fee paid under subparagraph (B) for any order request which is refused for filing or was withdrawn before being accepted or refused for filing.

  * #### (F) Fees for order requests previously refused for filing or withdrawn before filing
    * An OTC monograph order request that was submitted but was refused for filing, or was withdrawn before being accepted or refused for filing, shall be subject to the full fee under subparagraph (A) upon being resubmitted or filed over protest.

  * #### (G) Refund of fee if order request withdrawn
    * If an order request is withdrawn after the order request was filed, the Secretary may refund the fee or a portion of the fee if no substantial work was performed on the order request after the application was filed. The Secretary shall have the sole discretion to refund a fee or a portion of the fee under this subparagraph. A determination by the Secretary concerning a refund under this subparagraph shall not be reviewable.

* #### (3) Refunds
  * #### (A) In general
    * Other than refunds provided pursuant to any of subparagraphs (D) through (G) of paragraph (2), the Secretary shall not refund any fee paid under paragraph (1) except as provided in subparagraph (B).

  * #### (B) Disputes concerning fees
    * To qualify for the return of a fee claimed to have been paid in error under paragraph (1) or (2), a person shall submit to the Secretary a written request justifying such return within 180 calendar days after such fee was paid.

* #### (4) Notice
  * Within the timeframe specified in subsection (c), the Secretary shall publish in the Federal Register the amount of the fees under paragraph (1) for such fiscal year.

#### (b) Fee revenue amounts
* #### (1) Fiscal year 2021
  * For fiscal year 2021, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—

    * (A) the annual base revenue for fiscal year 2021 (as determined under paragraph (3));

    * (B) the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(2)); and

    * (C) additional direct cost adjustments (as determined under subsection (c)(3)).

* #### (2) Subsequent fiscal years
  * For each of the fiscal years 2022 through 2025, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—

    * (A) the annual base revenue for the fiscal year (as determined under paragraph (3));

    * (B) the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1));

    * (C) the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(2));

    * (D) additional direct cost adjustments (as determined under subsection (c)(3)); and

    * (E) additional dollar amounts for each fiscal year as follows:

      * (i) $7,000,000 for fiscal year 2022.

      * (ii) $6,000,000 for fiscal year 2023.

      * (iii) $7,000,000 for fiscal year 2024.

      * (iv) $3,000,000 for fiscal year 2025.

* #### (3) Annual base revenue
  * For purposes of paragraphs (1)(A) and (2)(A), the dollar amount of the annual base revenue for a fiscal year shall be—

    * (A) for fiscal year 2021, $8,000,000; and

    * (B) for fiscal years 2022 through 2025, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made under subsection (c)(2) or (c)(3).

#### (c) Adjustments; annual fee setting
* #### (1) Inflation adjustment
  * #### (A) In general
    * For purposes of subsection (b)(2)(B), the dollar amount of the inflation adjustment to the annual base revenue for fiscal year 2022 and each subsequent fiscal year shall be equal to the product of—

      * (i) such annual base revenue for the fiscal year under subsection (b)(2); and

      * (ii) the inflation adjustment percentage under subparagraph (C).

  * #### (B) OTC monograph order request fees
    * For purposes of subsection (a)(2), the dollar amount of the inflation adjustment to the fee for OTC monograph order requests for fiscal year 2022 and each subsequent fiscal year shall be equal to the product of—

      * (i) the applicable fee under subsection (a)(2) for the preceding fiscal year; and

      * (ii) the inflation adjustment percentage under subparagraph (C).

  * #### (C) Inflation adjustment percentage
    * The inflation adjustment percentage under this subparagraph for a fiscal year is equal to—

      * (i) for each of fiscal years 2022 and 2023, the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data; and

      * (ii) for each of fiscal years 2024 and 2025, the sum of—

        * (I) the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 years of the preceding 4 fiscal years, multiplied by the proportion of personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years; and

        * (II) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years.

* #### (2) Operating reserve adjustment
  * #### (A) In general
    * For fiscal year 2021 and subsequent fiscal years, for purposes of subsections (b)(1)(B) and (b)(2)(C), the Secretary may, in addition to adjustments under paragraph (1), further increase the fee revenue and fees if such an adjustment is necessary to provide operating reserves of carryover user fees for OTC monograph drug activities for not more than the number of weeks specified in subparagraph (B).

  * #### (B) Number of weeks
    * The number of weeks specified in this subparagraph is—

      * (i) 3 weeks for fiscal year 2021;

      * (ii) 7 weeks for fiscal year 2022;

      * (iii) 10 weeks for fiscal year 2023;

      * (iv) 10 weeks for fiscal year 2024; and

      * (v) 10 weeks for fiscal year 2025.

  * #### (C) Decrease
    * If the Secretary has carryover balances for such process in excess of 10 weeks of the operating reserves referred to in subparagraph (A), the Secretary shall decrease the fee revenue and fees referred to in such subparagraph to provide for not more than 10 weeks of such operating reserves.

  * #### (D) Rationale for adjustment
    * If an adjustment under this paragraph is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (4) establishing fee revenue and fees for the fiscal year involved.

* #### (3) Additional direct cost adjustment
  * The Secretary shall, in addition to adjustments under paragraphs (1) and (2), further increase the fee revenue and fees for purposes of subsection (b)(2)(D) by an amount equal to—

    * (A) $14,000,000 for fiscal year 2021;

    * (B) $7,000,000 for fiscal year 2022;

    * (C) $4,000,000 for fiscal year 2023;

    * (D) $3,000,000 for fiscal year 2024; and

    * (E) $3,000,000 for fiscal year 2025.

* #### (4) Annual fee setting
  * #### (A) Fiscal year 2021
    * The Secretary shall, not later than the second Monday in May of 2020—

      * (i) establish OTC monograph drug facility fees for fiscal year 2021 under subsection (a), based on the revenue amount for such year under subsection (b) and the adjustments provided under this subsection; and

      * (ii) publish fee revenue, facility fees, and OTC monograph order requests in the Federal Register.

  * #### (B) Subsequent fiscal years
    * The Secretary shall, for each fiscal year that begins after September 30, 2021, not later than the second Monday in March that precedes such fiscal year—

      * (i) establish for such fiscal year, based on the revenue amounts under subsection (b) and the adjustments provided under this subsection—

        * (I) OTC monograph drug facility fees under subsection (a)(1); and

        * (II) OTC monograph order request fees under subsection (a)(2); and


      * (ii) publish such fee revenue amounts, facility fees, and OTC monograph order request fees in the Federal Register.

#### (d) Identification of facilities
* Each person that owns an OTC monograph drug facility shall submit to the Secretary the information required under this subsection each year. Such information shall, for each fiscal year—

  * (1) be submitted as part of the requirements for drug establishment registration set forth in section 360 of this title; and

  * (2) include for each such facility, at a minimum, identification of the facility's business operation as that of an OTC monograph drug facility.

#### (e) Effect of failure to pay fees
* #### (1) OTC monograph drug facility fee
  * #### (A) In general
    * Failure to pay the fee under subsection (a)(1) within 20 calendar days of the due date as specified in subparagraph (D) of such subsection shall result in the following:

      * (i) The Secretary shall place the facility on a publicly available arrears list.

      * (ii) All OTC monograph drugs manufactured in such a facility or containing an ingredient manufactured in such a facility shall be deemed misbranded under section 352(ff) of this title.

  * #### (B) Application of penalties
    * The penalties under this paragraph shall apply until the fee established by subsection (a)(1) is paid.

* #### (2) Order requests
  * An OTC monograph order request submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for filing by the Secretary until all fees owed by such person under this section have been paid.

* #### (3) Meetings
  * A person subject to fees under this section shall be considered ineligible for OTC monograph drug meetings until all such fees owed by such person have been paid.

#### (f) Crediting and availability of fees
* #### (1) In general
  * Fees authorized under subsection (a) shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees are authorized to remain available until expended. Such sums as may be necessary may be transferred from the Food and Drug Administration salaries and expenses appropriation account without fiscal year limitation to such appropriation account for salaries and expenses with such fiscal year limitation. The sums transferred shall be available solely for OTC monograph drug activities.

* #### (2) Collections and appropriation Acts
  * #### (A) In general
    * Subject to subparagraph (C), the fees authorized by this section shall be collected and available in each fiscal year in an amount not to exceed the amount specified in appropriation Acts, or otherwise made available for obligation, for such fiscal year.

  * #### (B) Use of fees and limitation
    * The fees authorized by this section shall be available to defray increases in the costs of the resources allocated for OTC monograph drug activities (including increases in such costs for an additional number of full-time equivalent positions in the Department of Health and Human Services to be engaged in such activities), only if the Secretary allocates for such purpose an amount for such fiscal year (excluding amounts from fees collected under this section) no less than $12,000,000, multiplied by the adjustment factor applicable to the fiscal year involved under subsection (c)(1).

  * #### (C) Compliance
    * The Secretary shall be considered to have met the requirements of subparagraph (B) in any fiscal year if the costs funded by appropriations and allocated for OTC monograph drug activities are not more than 15 percent below the level specified in such subparagraph.

  * #### (D) Provision for early payments in subsequent years
    * Payment of fees authorized under this section for a fiscal year (after fiscal year 2021), prior to the due date for such fees, may be accepted by the Secretary in accordance with authority provided in advance in a prior year appropriations Act.

* #### (3) Authorization of appropriations
  * For each of the fiscal years 2021 through 2025, there is authorized to be appropriated for fees under this section an amount equal to the total amount of fees assessed for such fiscal year under this section.

#### (g) Collection of unpaid fees
* In any case where the Secretary does not receive payment of a fee assessed under subsection (a) within 30 calendar days after it is due, such fee shall be treated as a claim of the United States Government subject to subchapter II of chapter 37 of title 31.

#### (h) Construction
* This section may not be construed to require that the number of full-time equivalent positions in the Department of Health and Human Services, for officers, employers, and advisory committees not engaged in OTC monograph drug activities, be reduced to offset the number of officers, employees, and advisory committees so engaged.

### §379j–73. Reauthorization; reporting requirements
#### (a) Performance report
* Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 3861(b) of the CARES Act during such fiscal year and the future plans of the Food and Drug Administration for meeting such goals.

#### (b) Fiscal report
* Not later than 120 calendar days after the end of fiscal year 2021 and each subsequent fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.

#### (c) Public availability
* The Secretary shall make the reports required under subsections (a) and (b) available to the public on the internet website of the Food and Drug Administration.

#### (d) Reauthorization
* #### (1) Consultation
  * In developing recommendations to present to the Congress with respect to the goals described in subsection (a), and plans for meeting the goals, for OTC monograph drug activities for the first 5 fiscal years after fiscal year 2025, and for the reauthorization of this subpart for such fiscal years, the Secretary shall consult with—

    * (A) the Committee on Energy and Commerce of the House of Representatives;

    * (B) the Committee on Health, Education, Labor, and Pensions of the Senate;

    * (C) scientific and academic experts;

    * (D) health care professionals;

    * (E) representatives of patient and consumer advocacy groups; and

    * (F) the regulated industry.

* #### (2) Public review of recommendations
  * After negotiations with the regulated industry, the Secretary shall—

    * (A) present the recommendations developed under paragraph (1) to the congressional committees specified in such paragraph;

    * (B) publish such recommendations in the Federal Register;

    * (C) provide for a period of 30 calendar days for the public to provide written comments on such recommendations;

    * (D) hold a meeting at which the public may present its views on such recommendations; and

    * (E) after consideration of such public views and comments, revise such recommendations as necessary.

* #### (3) Transmittal of recommendations
  * Not later than January 15, 2025, the Secretary shall transmit to the Congress the revised recommendations under paragraph (2), a summary of the views and comments received under such paragraph, and any changes made to the recommendations in response to such views and comments.